Tag: chronic plaque psoriasis

1. A significantly greater percentage of both roflumilast groups had clear or nearly clear skin compared to the control group after 6 weeks of treatment. 2. A numerically higher number of patients in the higher-dose group achieved the primary outcome, but no statistically significant difference was detected between the treatment...
In this randomized controlled trial, 605 patients with moderate-to-severe chronic plaque psoriasis were assigned to receive 150 mg risankizumab subcutaneously at weeks 0 and 4, or 80 mg of adalimumab subcutaneously, and then 40 mg at weeks 1, 3, 5 and every other week thereafter during a 16-week treatment...